LyondellBasell has posted a quiet but meaningful bounce since its Q3 earnings report landed July 31, and the week's most striking dynamic is the gap between a Street that just spent two weeks cutting targets and is now scrambling to raise them — while short sellers have been quietly covering for a month.
The short-covering story is the cleaner one. Short interest has dropped 21% over the past month, falling from roughly 14.5 million shares in early July to 11.4 million now, taking the float percentage down to 3.5%. That decline accelerated through the July earnings cycle, not after it, suggesting shorts were not waiting for the print to exit. The borrow market shows no friction at all: availability is effectively unconstrained at the maximum reported level, with cost to borrow running at just 0.49% — up 33% over the past month but still trivially cheap in absolute terms. None of that points to squeeze pressure. It points to a measured, persistent unwind by sellers who had built a position through Q2 and are now scaling it back.
Options tell a different story. The put/call ratio on LYB has been elevated all year, and it remains so — running at 1.51 against a 20-day average of 1.49. The z-score is essentially flat, meaning there is no fresh escalation of hedging demand this week, but the absolute level of put protection is still at the higher end of the past twelve months. The 52-week PCR range runs from 0.73 to 1.87, placing the current reading in the upper third. Buyers have been persistently cautious on LYB for months, and that posture has not unwound alongside the short covering.
The analyst reaction to the July 31 print has been striking for its direction. In the two weeks before earnings, the tone was mostly defensive: Morgan Stanley trimmed its target from $77 to $72 in mid-July, and BMO had slashed from $88 to $64 in early July. The print has reversed that flow almost entirely. JP Morgan upgraded to Overweight from Neutral on August 3 and lifted its target to $80. RBC raised to $72 from $65. UBS went from $56 to $64. BMO, which had just cut, reversed to $68. The consensus mean target now sits at $69.53, implying roughly 14% upside to the $61.11 close. The earnings move itself was muted — a gain of less than 0.3% on the day — which is notable given how much negative pre-positioning existed. Bulls point to improving O&P-NA margins, tightening supply-demand dynamics, and moderate feedstock costs. Bears, still present via the elevated PCR, retain concerns about global overcapacity and fragile industrial demand.
The factor picture adds texture. The analyst recommendation divergence factor scores in the 97th percentile — an unusually wide gap in views that the post-earnings target-raising has only partially narrowed. EPS momentum over 90 days ranks at the bottom of the universe (10th percentile), while 12-month forward EPS change ranks in the 72nd, suggesting estimates are still moving up on a forward basis even if recent trend has been soft. The dividend factor scores at the 81st percentile — LYB has historically been a capital-return story, though the latest dividend data in this snapshot predates 2023 and recent dividend details should be verified separately. The short score itself has been drifting lower for two weeks, landing at 35.4, consistent with the short-interest unwind.
Peer divergence is worth noting this week. DOW — the closest correlated name at 91.8% — rose 5.1% on the week, essentially matching LYB's 5% gain, suggesting the move reflects a sector bid as much as a LYB-specific re-rating. OLN and LXU both fell sharply on the week, down 10.9% and 14.2% respectively, highlighting that the chemicals space is not moving uniformly and that LYB's post-earnings stability looks relatively resilient within the group.
The next scheduled print is October 30. Between now and then, the key watch will be whether the analyst upgrade cycle continues to narrow the gap to the mean target, and whether options participants — who have maintained elevated put positioning all year — begin to rotate toward a more balanced stance as the post-earnings dust settles.
See the live data behind this article on ORTEX.
Open LYB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
